Posted: 27th August 2018
SVI's Metabolic Signalling Lab, led by Associate Professor Jon Oakhill, has been awarded almost $100,000 through the Victorian Medical Research Acceleration Fund to uncover new drug targets and treatment strategies for type 2 diabetes. The Fund is an initiative under Victoria's Health and Medical Research Strategy 2016-2020, which outlines key priorities over four years to support new and evolving fields of world class medical research.
Type 2 diabetes affects more than 415 million people globally resulting in high blood glucose levels that lead to heat and blood vessel disease, and damage to nerves, kidneys and eyes. SVI has pioneered an approach in conjunction with the Monash Institute of Pharmaceutical Sciences, to reduce blood glucose and to stimulate uptake into skeletal muscle. These breakthroughs will allow us to identify areas important for drug action, by exploiting recent advances in our understanding of the cellular mechanisms involved in diabetes to uncover new drug targets and treatment strategies.
The Victorian Medical Research Acceleration Fund aims to support those in the early stages of health and medical research to translate their work into health and economic outcomes, and provides $3 million per annum to help address current market gaps and deliver rewards for research. It supports a small number of research proposals to 'fast track' translation into health and economic outcomes. Matching funds will by provided by SVI, to demonstrate the capacity to collaborate and undertake research that has a clear pathway to translation.
Learn more about the Fund here.